CLRB · Cellectar Biosciences, Inc.
$2.59
+0.00 (+0.00%)
At close · Aug 21
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$24.48M
Shares
9.45M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $3,042,750 |
| Jarrod Longcor | Chief Operating Officer | $1,830,000 |
| Chad Kolean | Chief Financial Officer | $1,223,400 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $1,965,140 |
| Jarrod Longcor | Chief Operating Officer | $1,362,560 |
| Chad Kolean | Chief Financial Officer | $1,108,960 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $1,463,172 |
| Jarrod Longcor | Chief Operating Officer | $831,755 |
| Chad Kolean | Chief Financial Officer | $461,643 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $2,151,250 |
| Jarrod Longcor | Chief Operating Officer | $891,446 |
| Dov Elefant | Former Vice President and Chief Financial Officer | $838,150 |
| John E. Friend II | Former Vice President and Chief Medical Officer | $706,549 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $1,016,240 |
| Igor Grachev | M.D., Ph.D. | $584,076 |
| Jarrod Longcor | Chief Operating Officer and Former Chief Business Officer | $574,507 |
| Dov Elefant | Former Vice President and Chief Financial Officer | $471,860 |
| John E. Friend II | Former Vice President and Chief Medical Officer | $386,310 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $934,460 |
| Jarrod Longcor | Chief Business Officer | $539,303 |
| Dov Elefant | Vice President and Chief Financial Officer | $312,437 |
| Charles T. Bernhardt | — | $187,313 |
| Brian Posner | Former Vice President and Chief Financial Officer | $63,219 |
| Former Chief Medical | Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $770,012 |
| Jarrod Longcor | Chief Business Officer | $477,888 |
| Brian Posner | Former Vice President and Chief Financial Officer | $417,376 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Douglas J. Swirsky | Class III director | Appointed | 2026-07-10 |
| Andrew Gu | Class III director | Appointed | 2026-07-10 |
| Andrew Gu | Class III director | Appointed | 2026-05-18 |
| John Neis | Class I director | Appointed | 2024-06-14 |
| Asher Chanan-Khan, M.B.B.S., M.D. | Class I director | Appointed | 2024-06-14 |
| Douglas J. Swirsky | Class III director | Appointed | 2023-06-29 |
| Stefan D. Loren | Class III director | Appointed | 2023-06-29 |
| Frederick W. Driscoll | Class II director | Appointed | 2022-06-27 |
| James V. Caruso | Class II director | Appointed | 2022-06-27 |
| Chad Kolean | Chief Financial Officer | Appointed | 2022-02-25 |
| Jarrod Longcor | Chief Operating Officer | Appointed | 2022-02-25 |
| Dov Elefant | Chief Financial Officer | Resigned | 2022-02-25 |
| Dr. Laurence Reilly | Interim Chief Medical Officer | Appointed | 2021-11-02 |
| Asher Chanan-Khan | Class I director | Appointed | 2021-06-24 |
| John Neis | Class I director | Appointed | 2021-06-24 |
| Dr. Igor Grachev | Dr. | Resigned | 2020-07-01 |
| Dr. John Friend | chief medical officer | Appointed | 2020-07-01 |
| John Friend II, M.D. | Vice President and Chief Medical Officer | Appointed | 2020-07-01 |
| Douglas J. Swirsky | Class III director | Appointed | 2020-06-25 |
| Stefan D. Loren | Class III director | Appointed | 2020-06-25 |
| Igor Grachev | Chief Medical Officer | Appointed | 2020-01-07 |
Key facts
CIK
1279704
CUSIP
15117F880
13F (30d)
33 filings
27 filers
Visit website
Investor relations